KemPharm, Inc. to Present at 16th Annual BIO CEO & Investor Conference - kcentv.com - KCEN HD - Waco, Temple, and Killeen

KemPharm, Inc. to Present at 16th Annual BIO CEO & Investor Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE KemPharm, Inc.

CORALVILLE, Iowa, Feb. 5, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that president and CEO, Travis Mickle, Ph.D., will present at the 16th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City. 

Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's development pipeline, including KP201, the company's lead clinical candidate for the treatment of acute moderate to moderately severe pain.  Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). 

Details of KemPharm's presentation are as follows:

Event:


16th Annual BIO CEO & Investor Conference

Date: 


Monday, February 10, 2014

Time: 


10:45 am, EST

Location:


Park South - Waldorf Astoria

A live audio-webcast of the presentation will be available via KemPharm's corporate website (http://www.kempharm.com) under Investor Relations and an archive will be accessible for 90 days following the presentation date.  

About KemPharm

KemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the first quarter of 2015. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com.

For KemPharm, Inc:   

Media / Investor Contacts:

Christal Mickle

319-665-2575

info@kempharm.com

Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020

jrando@tiberend.com

jdrumm@tiberend.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KCEN, Owned and Operated by London Broadcasting Company. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.